MA52415A - Dérivés de triazine pour le traitement de maladies associées à des neurotrophines - Google Patents

Dérivés de triazine pour le traitement de maladies associées à des neurotrophines

Info

Publication number
MA52415A
MA52415A MA052415A MA52415A MA52415A MA 52415 A MA52415 A MA 52415A MA 052415 A MA052415 A MA 052415A MA 52415 A MA52415 A MA 52415A MA 52415 A MA52415 A MA 52415A
Authority
MA
Morocco
Prior art keywords
neurotrophins
treatment
diseases associated
triazine derivatives
triazine
Prior art date
Application number
MA052415A
Other languages
English (en)
Inventor
Pontus Forsell
Gunnar Nordvall
Original Assignee
AlzeCure Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810667.4A external-priority patent/GB201810667D0/en
Application filed by AlzeCure Pharma AB filed Critical AlzeCure Pharma AB
Publication of MA52415A publication Critical patent/MA52415A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • C07D251/34—Cyanuric or isocyanuric esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052415A 2018-02-26 2019-02-26 Dérivés de triazine pour le traitement de maladies associées à des neurotrophines MA52415A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1850217 2018-02-26
GBGB1810667.4A GB201810667D0 (en) 2018-06-28 2018-06-28 New compounds and uses

Publications (1)

Publication Number Publication Date
MA52415A true MA52415A (fr) 2021-01-06

Family

ID=65729389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052415A MA52415A (fr) 2018-02-26 2019-02-26 Dérivés de triazine pour le traitement de maladies associées à des neurotrophines

Country Status (24)

Country Link
US (3) US11352332B2 (fr)
EP (1) EP3759088B8 (fr)
JP (1) JP7350759B2 (fr)
KR (1) KR102782749B1 (fr)
CN (1) CN111819172B (fr)
AU (1) AU2019223333B2 (fr)
BR (1) BR112020017341A2 (fr)
CA (1) CA3090864A1 (fr)
CL (1) CL2020002157A1 (fr)
DK (1) DK3759088T3 (fr)
ES (1) ES2941529T3 (fr)
FI (1) FI3759088T3 (fr)
HR (1) HRP20230290T1 (fr)
HU (1) HUE061751T2 (fr)
IL (1) IL276624B2 (fr)
LT (1) LT3759088T (fr)
MA (1) MA52415A (fr)
MX (1) MX2020008816A (fr)
PL (1) PL3759088T3 (fr)
PT (1) PT3759088T (fr)
SG (1) SG11202007136VA (fr)
SI (1) SI3759088T1 (fr)
WO (1) WO2019162702A1 (fr)
ZA (1) ZA202004220B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529819B2 (en) * 2017-06-08 2022-12-20 Nippon Soda Co., Ltd. Recording material and compound
US11352332B2 (en) 2018-02-26 2022-06-07 AlzeCure Pharma AB Triazine derivatives for treating diseases relating to neurotrophins
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) * 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds
WO2021259224A1 (fr) * 2020-06-23 2021-12-30 沈阳中化农药化工研发有限公司 Composé triazine benzoate et son application
CN113831298B (zh) * 2020-06-23 2023-12-01 沈阳中化农药化工研发有限公司 光活性羧酸酯类化合物及其应用
CN113831299B (zh) * 2020-06-23 2023-12-01 沈阳中化农药化工研发有限公司 苯甲酸酯类化合物及其应用
WO2022203395A1 (fr) * 2021-03-23 2022-09-29 한국과학기술연구원 Nouveau composé et composition le comprenant pour la prévention ou le traitement d'une maladie dégénérative du cerveau
CN118216517B (zh) * 2022-12-21 2025-06-24 沈阳中化农药化工研发有限公司 一种除草组合物及其应用
WO2025232990A1 (fr) 2024-05-09 2025-11-13 AlzeCure Pharma AB Dérivés de triazinone destinés à être utilisés dans le traitement d'une inflammation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246109A1 (de) * 1972-09-20 1974-03-28 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazinderivate, ein verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2313721A1 (de) * 1973-03-20 1974-10-03 Bayer Ag Neue 1-phenylsubstituierte 1,3,5triazine, verfahren zu ihrer herstellung, sowie ihre verwendung als arzneimittel
DE2413722C3 (de) * 1974-03-21 1982-04-08 Bayer Ag, 5090 Leverkusen Neue 1-(4-Phenoxy-phenyl)-1,3,5-triazin-Derivate, ein Verfahren zu ihrer Herstellung sowie ihre Anwendung als Arzneimittel
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
EP0081142B1 (fr) 1981-12-03 1986-06-25 BASF Aktiengesellschaft 1,3,5-Triazinones, procédé pour leur préparation et leur utilisation pour lutter contre la croissance indésirable de plantes
DE3314739A1 (de) 1983-04-23 1984-10-25 Bayer Ag, 5090 Leverkusen 1-(4-(4-(fluoralkylmethylthio- oder -sulfinyl- oder -sulfonyl-)phenoxy) phenyl)-1,3,5-triazin-2,4,6(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als coccidiosemittel
DE3408768A1 (de) * 1984-03-09 1985-09-12 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
DE3516632A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,3,5-triazintrionen
DE3516631A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 3-methyl-1,3,5-triazintrionen
DE3703105A1 (de) 1987-02-03 1988-08-11 Bayer Ag Mittel gegen protozoen bei insekten
DE3810080A1 (de) 1988-03-25 1989-10-05 Bayer Ag Trisubstituierte 1,3,5-triazin-2,4,6-trione
DE3814323A1 (de) 1988-04-28 1989-11-09 Hoechst Ag Wasserloesliche zubereitungen von coccidiostatica
US4933341A (en) 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
DE4000624A1 (de) 1990-01-11 1991-07-18 Bayer Ag Fungizide verwendung von trisubstituierten 1,3,5-triazin-2,4,6-trionen, neue trisubstituierte 1,3,5-triazin-2,4,6-trione und verfahren zu ihrer herstellung
DE4329096A1 (de) 1993-08-30 1995-03-02 Bayer Ag Heterocyclylbenzoheterocyclen
US5519133A (en) 1995-06-02 1996-05-21 American Cyanamid Co. 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
CZ146296A3 (en) 1995-06-02 1997-04-16 American Cyanamid Co 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotriones, process of their preparation and herbicidal agents
US5604180A (en) 1995-06-02 1997-02-18 Crews, Jr.; Alvin D. 3-(3-aryloxyphenyl)-1 (substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
US5726126A (en) 1995-06-02 1998-03-10 American Cyanamid Company 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents
US5679791A (en) 1996-07-25 1997-10-21 American Cyanamid Company 1-(3-heterocyclylphenyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
HK1043019B (zh) 1998-10-08 2005-05-13 高新研究公司 用於预防和治疗原虫病的组合物和方法
HUP0104716A3 (en) 1998-12-22 2003-10-28 Bayer Corp Pittsburgh Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma and medicaments containing them
DE19937500A1 (de) 1999-08-09 2001-02-15 Bayer Ag Substituierte Heterocyclylbenzofurane
DE19958388A1 (de) 1999-12-03 2001-06-07 Bayer Ag Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten
US6444615B1 (en) 2000-04-18 2002-09-03 Dow Agrosciences Llc Herbicidal imidazolidinetrione and thioxo-imidazolidinediones
DE10034800A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Benzostickstoffheterocyclen
DE10040174A1 (de) 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
DE10040110A1 (de) 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfoxiden zur Bekämpfung von Coccidiosen
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
EP1437344A4 (fr) 2001-09-28 2006-09-20 Takeda Pharmaceutical Derives de benzene et procede de preparation et d'utilisation associe
US6861523B2 (en) 2002-02-08 2005-03-01 Torrey Pines Institute For Molecular Studies 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
BR0304925A (pt) 2002-05-30 2004-09-28 Solvay Pharm Bv Compostos, composições farmacêuticas, e, uso dos compostos
AU2003251010A1 (en) 2002-07-15 2004-02-02 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
DE102006038292A1 (de) 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
WO2008148008A1 (fr) 2007-05-23 2008-12-04 Emory University Dosage biologique a haut rendement servant a identifier des agonistes selectifs du recepteur trka, ainsi que l'amide gambogique, un agoniste selectif de trka presentant une activite neuroprotectrice
US20120004310A1 (en) 2010-05-28 2012-01-05 Longo Frank M Non-peptide bdnf neurotrophin mimetics
US9828330B2 (en) 2013-03-15 2017-11-28 Pharmatrophix, Inc. Non-peptide BDNF neurotrophin mimetics
RU2016131875A (ru) 2014-01-20 2018-02-26 Ф. Хоффманн-Ля Рош Аг Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы
CN117137048A (zh) 2014-12-10 2023-12-01 马斯公司 风味组合物、包含该组合物的食品及增加食品鲜味味道强度的方法
EP3558320A1 (fr) 2016-12-21 2019-10-30 Alzecure Pharma AB Dérivés de triazinetrione et leur utilisation en tant que modulateurs du récepteur de la neurotrophine et de tyrosines kinases réceptrices
US11352332B2 (en) 2018-02-26 2022-06-07 AlzeCure Pharma AB Triazine derivatives for treating diseases relating to neurotrophins
GB201810669D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds

Also Published As

Publication number Publication date
US20220306589A1 (en) 2022-09-29
LT3759088T (lt) 2023-05-10
WO2019162702A1 (fr) 2019-08-29
PT3759088T (pt) 2023-04-10
CN111819172B (zh) 2024-02-06
EP3759088B1 (fr) 2023-01-25
AU2019223333A1 (en) 2020-08-27
CN111819172A (zh) 2020-10-23
US11352332B2 (en) 2022-06-07
JP7350759B2 (ja) 2023-09-26
JP2021514963A (ja) 2021-06-17
KR102782749B1 (ko) 2025-03-18
DK3759088T3 (en) 2023-03-27
US20250214948A1 (en) 2025-07-03
CL2020002157A1 (es) 2020-12-18
EP3759088A1 (fr) 2021-01-06
IL276624B1 (en) 2023-06-01
CA3090864A1 (fr) 2019-08-29
ZA202004220B (en) 2023-12-20
HUE061751T2 (hu) 2023-08-28
ES2941529T3 (es) 2023-05-23
KR20200126988A (ko) 2020-11-09
RU2020126542A (ru) 2022-03-29
HRP20230290T1 (hr) 2023-05-26
IL276624B2 (en) 2023-10-01
EP3759088B8 (fr) 2023-03-08
BR112020017341A2 (pt) 2020-12-15
PL3759088T3 (pl) 2023-07-03
IL276624A (en) 2020-09-30
SI3759088T1 (sl) 2023-07-31
MX2020008816A (es) 2020-09-28
US20200399230A1 (en) 2020-12-24
SG11202007136VA (en) 2020-08-28
FI3759088T3 (fi) 2023-04-05
AU2019223333B2 (en) 2024-06-20
US12209071B2 (en) 2025-01-28

Similar Documents

Publication Publication Date Title
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA49767A (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
EP3820888A4 (fr) Systèmes co-récepteurs pour le traitement de maladies infectieuses
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
ZA202004220B (en) Triazine derivatives for treating diseases relating to neurotrophins
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3504204A4 (fr) Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie
EP3454896A4 (fr) Dérivés hétérocycliques pour le traitement de rsv
MA52218A (fr) Traitement de cancers associés à trk
DK3886858T3 (da) Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3773629A4 (fr) Thérapies à base de car-treg pour le traitement de maladies neurodégénératives
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
EP3405211A4 (fr) Octréotide par voie orale pour le traitement de maladies
EP3612214A4 (fr) Optimisation d'enzymothérapie de remplacement pour le traitement de l'homocystinurie
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
EP3735209A4 (fr) Traitement de la progression de la myopie
EP3877382A4 (fr) Nouveaux composés pour le traitement de maladies respiratoires
EP3413898A4 (fr) Utilisation de tréhalose pour le traitement de maladies neurologiques